Events - Event View
This is the "Event Detail" view, showing all available information for this event.
If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.
Topic: 'Creating and Protecting New Products and Technologies'
Innovation is one of the most important requirements for chemical, pharmaceutical and biotechnology companies to be successful. Unfortunately, simply creating new products and advancing technology in these fields is not enough. Companies must take sufficient steps to protect their intellectual property in order to thrive financially and provide consumers with a reliable, consistent experience using their products and services. Without this consistency, companies damage relationships with customers leading to loss of profit. The panel will address recent developments in the industry surrounding technology advances, building a successful intellectual property portfolio, and practical steps that companies of all sizes can use to protect their technology and brands.
Each speaker will give a presentation followed by a discussion moderated by Peter Young of Young & Partners.
About our Speakers:
|Patrice P. Jean,
Partner, Patent Law,
Hughes, Hubbard & Reed
||Susan M. Perkins, Esq.,
Vice President, Intellectual Property,
Patrice P. Jean, J.D.
Patrice P. Jean has extensive experience counseling leading and startup companies in all areas of intellectual property law. She is particularly adept at asserting and defending the patent rights underlying the core technologies and innovations of leading pharmaceutical, chemical and biotechnology companies. She also defends her clients against claims asserted by competitors. Patrice has an extensive technical background in the life sciences which can be critical to understand the complex science in life science prosecution and litigation matters, whether is it is the science behind client innovations or the broader market implications. Prior to law school, Patrice earned her Ph.D. in molecular biology. She conducted research in various areas of biology and biochemistry including virology, oncology, kidney disease, X-ray crystallography and narcotics addiction. Her doctoral thesis is titled “Tissue, Strain, Gender and Age Variation in the Induction of p53 Activated Transcripts in Response to Cellular Stress.” Columbia University, School of Law, J.D., Editor-in-Chief, Columbia Science & Technology Law Review, 2002; Princeton University, Ph.D., Molecular Biology, 1999 ; Princeton University, M.A., Molecular Biology, 1996; Xavier University of Louisiana, B.S., 1993
Susan Perkins, J.D.
Susan begun her career as a Patent Examiner at the U.S. Patent & Trademark Office over 20 years ago. Ms. Perkins joined Paratek Pharmaceuticals when it went public in 2014 in order to solidify the IP position of two late-stage anti-infectives, Omadacycline and Sarecycline, both currently under FDA review and preparing for commercialization. Prior to Paratek, Ms. Perkins was the sole in-house IP counsel for a number of start-up biotechnology companies, including Aileron Therapeutics (a leader in Stapled Peptide therapeutics), Avila Therapeutics (acquired by Celgene), Syntonix Pharmaceuticals (acquired by Biogen Idec) and Leukosite (acquired by Millennium Pharmaceuticals for which Ms. Perkins continued as patent counsel). Before going in-house, Susan was associated with the law firm of Campbell & Flores in San Diego, CA. She holds a J.D. with Honors from the George Washington University, which included an externship with the Honorable Randall Radar of the U.S. Court of Appeals for the Federal Circuit. Ms. Perkins holds an advanced degree in chemistry from the University of North Carolina, and graduated Summa Cum Laude from UMass-Amherst
Wednesday, October 17, 2018, 11:30 AM until 2:00 PM
The Yale Club
50 Vanderbilt Ave
New York, NY 10017
Danielle J Fraser